Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline

被引:0
作者
Francesco Panza
Vincenzo Solfrizzi
Anna M. Colacicco
Alessia D’Introno
Cristiano Capurso
Rossella Palasciano
Orlando Todarello
Sabrina Capurso
Vincenza Pellicani
Antonio Capurso
机构
[1] University of Bari - Policlinico,Department of Geriatrics, Center for Aging Brain, Memory Unit
[2] University of Foggia,Department of Geriatrics
[3] University of Bari,Department of Neurological and Psychiatric Sciences
来源
Aging Clinical and Experimental Research | 2006年 / 18卷
关键词
Alzheimer’s disease; cerebrovascular disease; mild cognitive impairment; predementia syndrome; total cholesterol; vascular dementia;
D O I
暂无
中图分类号
学科分类号
摘要
Data concerning the treatment of lipoprotein disturbances in patients with cerebrovascular disease (CVD) are less robust than those for coronary heart disease (CHD), raising clinical questions as to which is the appropriate therapeutic approach to stroke patients. Although observational cohort studies have failed to demonstrate an association between lipoprotein disorders and stroke incidence, recently completed trials of subjects at risk for CHD have shown that statins reduce not only the risk of myocardial infarction and death, but also that of brain infarction and transient ischemic attacks. At present, it seems reasonable to conclude that stroke patients with undesirable lipid profiles who have a history of CHD should receive specific treatment for the lipid disorder. Recommendations are more problematic for stroke patients with lipid disorder but no history of CHD. Furthermore, many of the risk factors for CVD and vascular dementia (VaD), including serum total cholesterol (TC), lipoprotein(a), diabetes, atrial fibrillation, hypertension, apolipoprotein E levels, and atherosclerosis, have also been shown to increase the risk of Alzheimer’s disease (AD). In a recent study, we estimated the prevalence, incidence and rate of progression of Mild Cognitive Impairment (MCI) to dementia, and correlated vascular risk factors with incident MCI and its progression to dementia. We evaluated 2963 individuals from the population-based sample of 5632 subjects 65–84 years old of the Italian Longitudinal Study on Aging, with a 3.5-year follow-up. We found a progression rate to dementia (all causes) of 3.8/100 person-years. Furthermore, age was a risk factor for incident MCI, while education was protective, and serum TC evidenced a non-significant borderline trend for a protective effect. There was a non-significant trend for stroke as a risk factor of progression of MCI to dementia. In conclusion, in our population, among MCI patients who progressed to dementia, 60% progressed to AD and 33% to VaD. Vascular risk factors and CVD may influence the development of MCI and the rate of progression to dementia.
引用
收藏
页码:144 / 148
页数:4
相关论文
共 79 条
  • [11] Blauw GJ(2001)Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal population based study BMJ 322 1447-51
  • [12] Murphy MB(2002)Apolipoprotein E epsilon4 allele; elevated midlife total cholesterol level; and high midlife systolic blood pressure are independent risk factor for late-life Alzheimer disease Ann Intern Med 137 149-55
  • [13] Sever PS(1997)Association between features of the insulin resistance syndrome and Alzheimer’s disease independently of apolipoprotein E4 phenotype: cross sectional population based study BMJ 315 1045-9
  • [14] Dahlof B(2002)Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer’s disease J Neurol Neurosurg Psychiatry 72 732-6
  • [15] Poulter NR(2002)Incidence and risk factors of dementia in a defined elderly Japanese population: the Hisayama study Ann NY Acad Sci 977 1-8
  • [16] Jarvik GP(1999)Factors associated with vascular dementia in an elderly community population Int J Psychiatry 14 761-6
  • [17] Wijsman EM(2002)Statins in the prevention and treatment of Alzheimer disease Alzheimer Dis Assoc Dis 16 131-6
  • [18] Kukull WA(2000)Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch Neurol 57 1439-43
  • [19] Schellenberg GD(2002)Use of lipid-lowering agents; indication bias; and the risk of dementia in community-dwelling elderly people Arch Neurol 59 223-7
  • [20] Yu C(2004)Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study Neurology 63 1624-8